Conecte-se

Bibliografias temáticas / Tumefactive demyelinating lesions / Artigos de revistas

Siga este link para ver outros tipos de publicações sobre o tema: Tumefactive demyelinating lesions.

Artigos de revistas sobre o tema "Tumefactive demyelinating lesions"

Autor: Grafiati

Publicado: 7 de junho de 2025

Última modificação: 2 de agosto de 2025

Crie uma referência precisa em APA, MLA, Chicago, Harvard, e outros estilos

Selecione um tipo de fonte:

Veja os 50 melhores artigos de revistas para estudos sobre o assunto "Tumefactive demyelinating lesions".

Ao lado de cada fonte na lista de referências, há um botão "Adicionar à bibliografia". Clique e geraremos automaticamente a citação bibliográfica do trabalho escolhido no estilo de citação de que você precisa: APA, MLA, Harvard, Chicago, Vancouver, etc.

Você também pode baixar o texto completo da publicação científica em formato .pdf e ler o resumo do trabalho online se estiver presente nos metadados.

Veja os artigos de revistas das mais diversas áreas científicas e compile uma bibliografia correta.

1

Barbosa, Brainner Campos, Edson Marchiori, Caio Leal Leidersnaider, Lara Brandao, and Mauricio Castillo. "Demyelinating lesions behaving like aggressive tumours on advanced MRI techniques." Neuroradiology Journal 32, no. 2 (2019): 103–7. http://dx.doi.org/10.1177/1971400919826394.

Texto completo da fonte

Resumo:

Tumefactive demyelinating lesions are a rare disorder in which inflammatory demyelination manifests as solitary or multiple focal brain lesions (greater than 2 cm in size), which can be mistaken for glioma, lymphoma, metastasis and in some cases even brain abscess. The symptomatology of tumefactive demyelinating lesions depends on the white matter area involved and includes quickly progressing neurological deterioration of motor, sensory and visual function, praxis, language and mood impairment, as well as seizures. Recognising the key imaging features in a patient with a prior history of demy

Estilos ABNT, Harvard, Vancouver, APA, etc.

2

Brod, Staley A., J. William Lindsey, and Flavia Nelson. "Tumefactive demyelination: Clinical outcomes, lesion evolution and treatments." Multiple Sclerosis Journal - Experimental, Translational and Clinical 5, no. 2 (2019): 205521731985575. http://dx.doi.org/10.1177/2055217319855755.

Texto completo da fonte

Resumo:

Objective Large demyelinating lesions with possible mass effect (tumefactive multiple sclerosis or tumefactive demyelination) can be mistaken for tumour-like space-occupying lesions suggesting a malignant outcome. Methods We reviewed our own experience of multiple sclerosis subjects ( n = 28) with tumefactive demyelination to determine the relationship between clinical outcomes and lesion evolution, clinical outcomes and their relationship to different therapies. Patients with central nervous system demyelinating disease were identified from our database over the last 10 years. Results No pati

Estilos ABNT, Harvard, Vancouver, APA, etc.

3

Weinshenker, Brian G. "Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?" Multiple Sclerosis Journal 21, no. 13 (2015): 1746–47. http://dx.doi.org/10.1177/1352458515603801.

Texto completo da fonte

Resumo:

Whether or not recurrent tumefactive demyelinating lesions are a unique form of CNS demyelinating disease or part of the continuum of multiple sclerosis is a question raised by the case report on which this commentary is based. Detailed review and immunopathologic study of biopsy material may not only confirm or refute a diagnosis of demyelinating disease, but potentially uncover unique features that may assist in understanding pathophysiology and nosology of rare cases with recurrent tumefactive demyelination.

Estilos ABNT, Harvard, Vancouver, APA, etc.

4

Hudon, Mark, Richard Farb, A. P. Mitha, et al. "Tumefactive Demyelinating Lesions." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 34, no. 3 (2007): 362–64. http://dx.doi.org/10.1017/s0317167100006831.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

5

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/s002340050308.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

6

Dagher, A. P., and J. Smirniotopoulos. "Tumefactive demyelinating lesions." Neuroradiology 38, no. 6 (1996): 560–65. http://dx.doi.org/10.1007/bf00626098.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

7

Zafar, Lubna, Obaid Ahmed Siddiqui, Shazia Durdana, and Damera Achyuth Kumar. "Tumefactive demyelination-A Rare Presentation of Multiple Sclerosis." Bangladesh Journal of Medical Science 21, no. 4 (2022): 931–34. http://dx.doi.org/10.3329/bjms.v21i4.60259.

Texto completo da fonte

Resumo:

Background: Multiple Sclerosis is an inflammatory demyelinating disease having varied manifestations in terms of clinical featuresand radiological features. Rarely it may present as a large demyelinating lesionwith accompanying edema and mass effect, thereby simulating an intracranial tumor, known as Tumefactive Demyelination. Symptoms are usually related to the pressure of a focal mass lesion. When it manifests in a patient without pre-existing MS, it poses a diagnostic challengeas it may mimic a neoplasm, infarct or abscess. Thus, it is essential to recognize this rare clinical entity for pr

Estilos ABNT, Harvard, Vancouver, APA, etc.

8

Kalanie, Hossein, Ali Amini Harandi, Reza Bakhshandehpour, and Daryoosh Heidari. "Multiple Large Tumefactive MS Plaques in a Young Man: A Diagnostic Enigma and Therapeutic Challenge." Case Reports in Radiology 2012 (2012): 1–5. http://dx.doi.org/10.1155/2012/363705.

Texto completo da fonte

Resumo:

Tumefactive demyelinating lesion is defined as large solitary demyelinating lesion with imaging characteristics mimicking neoplasm. These atypical features include size more than 2 cm, mass effect, edema, and/or ring enhancement. Distinguishing tumefactive lesions from other etiologies of intracranial space occupying lesions is essential to avoid inadvertent surgical or toxic chemotherapeutic intervention. Symptoms are generally atypical for multiple sclerosis (MS) and usually related to the pressure of a focal mass lesion without a history of MS. The clinical presentation and MRI appearance o

Estilos ABNT, Harvard, Vancouver, APA, etc.

9

QI, WEI, GE JIA, XINSHENG WANG, MAOZHI ZHANG, and ZHENYU MA. "Cerebral tumefactive demyelinating lesions." Oncology Letters 10, no. 3 (2015): 1763–68. http://dx.doi.org/10.3892/ol.2015.3481.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

10

Altintas, A., B. Petek, N. Isik, et al. "Clinical and radiological characteristics of tumefactive demyelinating lesions: follow-up study." Multiple Sclerosis Journal 18, no. 10 (2012): 1448–53. http://dx.doi.org/10.1177/1352458512438237.

Texto completo da fonte

Resumo:

Background: Demyelinating lesions over 20 mm in size, referred to as tumefactive demyelinating lesions, can be misdiagnosed as being either a tumor or an abscess. Although some radiological characteristics can help make a differential diagnosis easier, a cerebral biopsy may still be necessary. Objective: Our objective was to assess the clinical characteristics of tumefactive lesions, with or without a diagnosis of multiple sclerosis (MS), and present follow-up data for 54 patients with tumefactive lesions. Methods: Demographic, clinical, radiological and laboratory data were gathered and treat

Estilos ABNT, Harvard, Vancouver, APA, etc.

11

Foo, See Yun, Nurul Hafidzah Rahim, Aida Widure Mustapha Mohd Mustapha, and Noraini Rose Mohd Zaini. "Magnetic Resonance Imaging (MRI) Features in Diagnosing Tumefactive Demyelinating Lesion." Journal Of Cardiovascular, Neurovascular & Stroke 4, no. 3 (2022): 14–20. http://dx.doi.org/10.32896/cvns.v4n3.14-20.

Texto completo da fonte

Resumo:

Background: A demyelinating lesion can present as a space occupying lesion in Magnetic Resonance Imaging (MRI) brain. Lesions that have diameter greater than 2 cm is referred as tumefactive demyelinating lesion. These lesions can mimic a brain tumor, namely glioma or primary central nervous system lymphoma. Case presentation: We present two female patients over 30 years old who presented with limb weakness. Their MRI demonstrated typical appearance of a solitary, incomplete rim enhancing lesion that involved the subcortical white matter with minimal mass effect. Also, the rim of enhancement op

Estilos ABNT, Harvard, Vancouver, APA, etc.

12

Koudriavtseva, Tatiana, Domenico Plantone, Carlo Piantadosi, Serena Ruggieri, and Vincenzo Anelli. "Tumefactive demyelinating lesions and pregnancy." Neurology India 67, no. 6 (2019): 1519. http://dx.doi.org/10.4103/0028-3886.273654.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

13

Fontes-Villalba, Ariadna A., Heath H. French, and John DE Parratt. "Characterisation of tumefactive demyelinating lesions." Journal of Neurology, Neurosurgery & Psychiatry 88, no. 5 (2017): e1.9-e1. http://dx.doi.org/10.1136/jnnp-2017-316074.14.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

14

Inshasi, Jihad Said, Pournamy Sarathchandran, Mona Chetan Thakre, Nouf Saeed Al Talai, Reem Al Suwaidi, and Abubaker Al Madani. "Oral Cladribine is Effective in the Treatment of Tumefactive Demyelination in Relapsing Remitting Multiple Sclerosis – A Case Report." Open Neurology Journal 14, no. 1 (2020): 109–14. http://dx.doi.org/10.2174/1874205x02014010109.

Texto completo da fonte

Resumo:

This case report describes a 32-year old Emirati patient with tumefactive multiple sclerosis (TMS) treated with a short course of cladribine tablets. The patient presented initially with acute onset of progressive gait unsteadiness, lower limb weakness, associated with numbness of four days duration. Neurological examination of right arms and both legs weakness with sensory level at T10. Contrast-enhanced magnetic resonance imaging (MRI) of the brain showed a large tumefactive demyelination with multiple demyelinating lesions in the brain, consistent with a diagnosis of multiple sclerosis. MRI

Estilos ABNT, Harvard, Vancouver, APA, etc.

15

Siffrin, Volker, Wibke Müller-Forell, Harald von Pein, and Frauke Zipp. "How to treat tumefactive demyelinating disease?" Multiple Sclerosis Journal 20, no. 5 (2013): 631–33. http://dx.doi.org/10.1177/1352458513516891.

Texto completo da fonte

Resumo:

Glioma-like inflammatory demyelinating lesions can be found in patients with pre-diagnosed multiple sclerosis, but they have also been described as an isolated disease entity. The initial diagnostic work-up usually includes a biopsy for histopathological analysis. However, even after unambiguous histopathologic classification, tumefactive lesions pose a therapeutic challenge. Until now, there have been no guidelines on how to treat patients with these rare and extreme lesion phenotypes. Here we report a patient with a relapsing unifocal tumefactive demyelinating lesion. The patient initially s

Estilos ABNT, Harvard, Vancouver, APA, etc.

16

Lin, Chi-Ju, Shih-Chieh Lin, Kai-Wei Yu, Wen-Yu Ou Yang, Yi-Chung Lee, and Yi-Chu Liao. "Tumefactive Demyelination Lesions: Report on Three Cases." Acta Neurologica Taiwanica 33, no. 4 (2024): 172–76. https://doi.org/10.4103/ant.33-4_112_0080.

Texto completo da fonte

Resumo:

Abstract Purpose: Tumefactive demyelination (TD) lesion and its subtype Balo’s concentric sclerosis (BCS), are rare manifestations of central nervous system demyelinating disease. Because of its rarity, physicians might hesitate in reaching a diagnosis or initiating steroid pulse therapy. This study aims at pinpointing the key neuroimaging features to distinguish TD lesions from surgical conditions, and illustrating the clinical outcomes of patients with TD lesions. Case report: Two of the three patients had solitary TD lesions, one 47-year-old man presenting with newly onset seizure and anoth

Estilos ABNT, Harvard, Vancouver, APA, etc.

17

Hardy, Todd A., W. Oliver Tobin, and Claudia F. Lucchinetti. "Exploring the overlap between multiple sclerosis, tumefactive demyelination and Baló’s concentric sclerosis." Multiple Sclerosis Journal 22, no. 8 (2016): 986–92. http://dx.doi.org/10.1177/1352458516641776.

Texto completo da fonte

Resumo:

The availability of magnetic resonance imaging (MRI) has led to increasing recognition that multiple sclerosis (MS), tumefactive demyelination (TD) and Baló’s concentric sclerosis (BCS) share many overlapping features. Baló-like lesions, which exhibit limited features of BCS, may represent an intermediate between BCS and typical MS demyelination. Lesions labeled as tumefactive are typically larger, but otherwise have much in common with conventional MS lesions, and TD and BCS lesions can also overlap. In this article, we explore the similarities between typical MS, TD and BCS cases, and reflec

Estilos ABNT, Harvard, Vancouver, APA, etc.

18

Manouchehri, Navid, Nasim Nehzat, Omid Mirmosayeb, Vahid Shaygannejad, and Mahdi Barzegar. "Tumefactive Brain Lesions in Patients with Neuromyelitis Optica Spectrum Disorder." Caspian Journal of Neurological Sciences 5, no. 2 (2019): 96–100. http://dx.doi.org/10.32598/cjns.5.17.96.

Texto completo da fonte

Resumo:

Background: Neuromyelitis Optica Spectrum Disorder (NMOSD) is an autoimmune neurological disorder that is characterized by optic neuritis and longitudinally-extended transverse myelitis lesions in spinal segments. Magnetic Resonance Imaging (MRI) findings are part of the diagnostic process in NMOSD patients, and abnormal lesion patterns may cause deviation from a correct diagnosis. Clinical Presentation and Intervention: A 43-year-old female patient with abrupt cognitive loss, motor dysfunction and tumefactive spread of the demyelinating lesions in her brain presented to the Neurology Clinic o

Estilos ABNT, Harvard, Vancouver, APA, etc.

19

Cereda, CW, C. Zecca, L. Mazzucchelli, et al. "Tumefactive demyelinating lesions during etanercept treatment requiring decompressive hemicraniectomy." Multiple Sclerosis Journal 19, no. 6 (2012): 820–23. http://dx.doi.org/10.1177/1352458512461969.

Texto completo da fonte

Resumo:

Tumor necrosis factor alpha (TNF-α) is a pro-inflammatory and immunoregulatory cytokine involved in the pathogenesis of several autoimmune disorders. Etanercept, a TNF-α antagonist (anti-TNF-α) acting as a soluble TNF-α receptor, has been associated with neurological demyelinating disorders. This paper aims to report an unusual case showing tumefactive central nervous system (CNS) inflammatory demyelination in a patient in the course of TNF -α antagonist therapy, requiring decompressive hemicraniectomy. This report is based on magnetic resonance imaging (MRI) findings and histology. A biopsy c

Estilos ABNT, Harvard, Vancouver, APA, etc.

20

Morin, Marie-Paule, Yves Patenaude, Anna B. Sinsky, Brenda Banwell, and Guillaume Sébire. "Solitary Tumefactive Demyelinating Lesions in Children." Journal of Child Neurology 26, no. 8 (2011): 995–99. http://dx.doi.org/10.1177/0883073811401402.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

21

Algahtani, Hussein, Bader Shirah, and Ali Alassiri. "Tumefactive demyelinating lesions: A comprehensive review." Multiple Sclerosis and Related Disorders 14 (May 2017): 72–79. http://dx.doi.org/10.1016/j.msard.2017.04.003.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

22

Haritanti, A., A. Lefkopoulos, E. Papadopoulou, et al. "Bilateral Tumefactive Multiple Sclerosis Lesions." Rivista di Neuroradiologia 18, no. 3 (2005): 365–70. http://dx.doi.org/10.1177/197140090501800313.

Texto completo da fonte

Resumo:

Tumefactive lesions are a rare form of multiple sclerosis (MS) presentation often provoking a diagnostic dilemma with brain tumour or abscess. We describe two cases of tumefactive demyelinating MS plaques and two different approaches. In the first patient the clinical and laboratory findings were consistent with MS, a diagnosis supported by the rapid response to high-dose steroid treatment. On the contrary, atypical clinical, imaging and laboratory findings in our second patient misled us to a diagnosis of a brain tumour. The diagnosis of MS was made after histopathological examination of the

Estilos ABNT, Harvard, Vancouver, APA, etc.

23

Omerhodžić, Ibrahim, Almir Džurlić, Dino Lisica, et al. "Relapsing Tumefactive Demyelination: A Case Report." Acta Medica Academica 47, no. 2 (2018): 193. http://dx.doi.org/10.5644/ama2006-124.231.

Texto completo da fonte

Resumo:

<p><strong>Objective. </strong>We present a case of relapsing tumefactive demyelination in a young female patient, that posed a real diagnostic challenge, with a heterogeneous clinical picture, atypical for multiple sclerosis (MS) presentation, and neuroradiological manifestations with a high suspicion of neoplastic diseases.</p><p><strong>Case Report</strong>. An 18-year old female patient presented to our Neurosurgical Out-patients’ Clinic with symptoms atypical for multiple sclerosis, unremarkable neurological deficit, one tumefactive lesion on MRI,

Estilos ABNT, Harvard, Vancouver, APA, etc.

24

Kang, Yu-jin, Sang-Gon Lee, and Suk-Won Ahn. "A Case of Multiple Sclerosis Presenting with Tumefactive Lesions." Journal of Multiple Sclerosis and Neuroimmunology 14, no. 2 (2023): 125–29. http://dx.doi.org/10.59578/jmsni.14.2.125.

Texto completo da fonte

Resumo:

Inflammatory demyelinating diseases including multiple sclerosis (MS) are usually diagnosed based on characteristic clinical and radiological findings. However, some demyelinating diseases have presented with growing large mass-like lesions, and it is difficult to differentiate those demyelinating lesions from brain tumors. We report a case of biopsy-proven MS mimicking brain tumor. This case suggests that inflammatory demyelinating diseases including MS have a wide spectrum and can present with the same radiological features as brain tumors such as lymphoma or high-grade glioma.

Estilos ABNT, Harvard, Vancouver, APA, etc.

25

Kang, Yu-jin, Sang-Gon Lee, and Suk-Won Ahn. "A Case of Multiple Sclerosis Presenting with Tumefactive Lesions." Journal of Multiple Sclerosis and Neuroimmunology 14, no. 2 (2023): 125–29. http://dx.doi.org/10.59578/jmsni.2023.14.2.125.

Texto completo da fonte

Resumo:

Inflammatory demyelinating diseases including multiple sclerosis (MS) are usually diagnosed based on characteristic clinical and radiological findings. However, some demyelinating diseases have presented with growing large mass-like lesions, and it is difficult to differentiate those demyelinating lesions from brain tumors. We report a case of biopsy-proven MS mimicking brain tumor. This case suggests that inflammatory demyelinating diseases including MS have a wide spectrum and can present with the same radiological features as brain tumors such as lymphoma or high-grade glioma.

Estilos ABNT, Harvard, Vancouver, APA, etc.

26

Enzinger, Christian, Siegrid Strasser-Fuchs, Stefan Ropele, Peter Kapeller, Reinhold Kleinert, and Franz Fazekas. "Tumefactive demyelinating lesions: conventional and advanced magnetic resonance imaging." Multiple Sclerosis Journal 11, no. 2 (2005): 135–39. http://dx.doi.org/10.1191/1352458505ms1145oa.

Texto completo da fonte

Resumo:

In rare instances, demyelinating disorders present with radiological features that mimic a brain tumour. This often leads to biopsy, which-apart from carrying significant morbidity-frequently turns out as nondiagnostic or dispensable. We therefore set out to assess the contribution of repeated conventional magnetic resonance imaging (MRI), 1H-MR spectroscopy and magnetization transfer imaging in establishing a correct diagnosis of tumefactive demyelinating lesions (TDLs). We studied two females and one male, who presented with TDLs that led to brain biopsy in two cases, for up to three years.

Estilos ABNT, Harvard, Vancouver, APA, etc.

27

Radhakrishnan, VV, SruthiS Nair, R. Neelima, et al. "Tumefactive demyelinating lesions: A Clinicopathological correlative study." Indian Journal of Pathology and Microbiology 55, no. 4 (2012): 496. http://dx.doi.org/10.4103/0377-4929.107788.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

28

Given, Curtis A., B. Scott Stevens, and Charles Lee. "The MRI Appearance of Tumefactive Demyelinating Lesions." American Journal of Roentgenology 182, no. 1 (2004): 195–99. http://dx.doi.org/10.2214/ajr.182.1.1820195.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

29

TürkoÄlu, Recai, Hans Lassmann, Fügen Vardar Aker, John Tzartos, Socrates Tzartos, and Erdem Tüzün. "Recurrent tumefactive demyelinating lesions: a pathological study." Clinical Neuropathology 36, no. 07 (2017): 195–98. http://dx.doi.org/10.5414/np301005.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

30

Charoensanti, Sudarat, Sutatip Pongcharoen, and Metha Apiwattanakul. "Pediatric Relapsing Anti-NMDAR Encephalitis Crossing with Tumefactive Demyelinating Lesion." Journal of Pediatric Neurology 17, no. 02 (2018): 077–84. http://dx.doi.org/10.1055/s-0038-1636994.

Texto completo da fonte

Resumo:

AbstractAnti-N-methyl-D-aspartate receptor (anti-NMDAR) encephalitis is an autoimmune encephalopathy characterized by neuropsychiatric symptoms, autonomic instability, and abnormal movements. Most children who undergo tumor removal and receive appropriate immunosuppressants have substantial neurological improvement. We report a 14-year-old girl with relapsing anti-NMDAR encephalitis who presented with paroxysmal tingling and weakness of the right lower limb. Despite long-term prophylaxis with immunotherapy (azathioprine), tumefactive demyelinating lesion and multifocal subcortical white matter

Estilos ABNT, Harvard, Vancouver, APA, etc.

31

Ekmekci, Ozgul, and Cenk Eraslan. "Silent Tumefactive Demyelinating Lesions and Radiologically Isolated Syndrome." Case Reports in Neurological Medicine 2018 (November 28, 2018): 1–5. http://dx.doi.org/10.1155/2018/8409247.

Texto completo da fonte

Resumo:

Demyelinating lesions larger than 2 cm in diameter, with or without edema, are known as tumefactive demyelinating lesions (TDLs). They constitute a rare inflammatory demyelinating disorder of the central nervous system. TDLs are typically characterized by headaches, cortical symptoms such as aphasia, hemiparesis, hemisensory deficits, seizures, and changes in consciousness. TDLs may occur in patients with or without an established diagnosis of MS or may occur as the initial demyelinating event. They may also be observed during follow-up in patients with MS, neuromyelitis optica, acute dissemin

Estilos ABNT, Harvard, Vancouver, APA, etc.

32

Pérez, Carlos A., Anish Patnaik, Sherwin Oommen, Alissa Redko, and Scott B. Mathis. "Tumefactive Demyelinating Lesions in Children: A Rare Case of Conus Medullaris Involvement and Systematic Review of the Literature." Journal of Child Neurology 35, no. 10 (2020): 690–99. http://dx.doi.org/10.1177/0883073820924147.

Texto completo da fonte

Resumo:

Tumefactive demyelinating lesions are an uncommon manifestation of demyelinating disease that mimic primary central nervous system neoplasms and can pose a diagnostic challenge in patients without a pre-existing diagnosis of multiple sclerosis. Although a biopsy may be required to distinguish TDL from neoplasms or infection, certain ancillary and radiographic findings may preclude the need for invasive diagnostic procedures. We describe the case of a 15-year-old boy with a tumefactive demyelinating lesion involving the conus medullaris. An exhaustive systematic literature search of pediatric c

Estilos ABNT, Harvard, Vancouver, APA, etc.

33

Sanghi, Avni, Grace Gombolay, and Tuba Khan. "Anti-myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorder (MOGAD) in a Pediatric Patient with Rare Presentation of a Cerebellar Tumefactive Lesion." Neurology 99, no. 23 Supplement 2 (2022): S17.3—S18. http://dx.doi.org/10.1212/01.wnl.0000903168.54950.6a.

Texto completo da fonte

Resumo:

ObjectiveNA.BackgroundAnti-myelin oligodendrocyte glycoprotein (MOG) antibodies have been commonly associated with optic neuritis, myelitis, and acute disseminated encephalomyelitis but rarely with tumefactive lesions, especially in children. We report a young child with MOGAD presenting with a tumefactive cerebellar demyelinating lesion.Design/MethodsA retrospective chart reviewResultsA 3-year-old developmentally appropriate boy with fever for five days prior presented for gait changes and a self-resolved seizure lasting less than 5 minutes. Neurologic examination showed abnormal finger to no

Estilos ABNT, Harvard, Vancouver, APA, etc.

34

Akimoto, Jiro, Tomohiro Suda, Ryo Hashimoto, Hirokazu Fukuhara, and Michihiro Kohno. "Magnetic Resonance Imaging Characteristics of Tumefactive Demyelinating Lesions." Journal of Biomedical Science and Engineering 08, no. 05 (2015): 321–26. http://dx.doi.org/10.4236/jbise.2015.85029.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

35

Weil, Erika L., and Mohammad Obadah Nakawah. "Recurrent tumefactive demyelinating lesions in an elderly woman." Radiology Case Reports 17, no. 12 (2022): 4570–74. http://dx.doi.org/10.1016/j.radcr.2022.09.008.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

36

Rovira, Alex. "Tumefactive idiopathic inflammatory demyelinating lesions: a diagnostic challenge." Multiple Sclerosis Journal 20, no. 5 (2013): 634–35. http://dx.doi.org/10.1177/1352458513517282.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

37

Galus, Weronika, Katarzyna Zawiślak-Fornagiel, and Ewa Krzystanek. "Tumefactive multiple sclerosis – a diagnostic and therapeutic challenge." Aktualności Neurologiczne 22, no. 3 (2023): 141–45. http://dx.doi.org/10.15557/an.2022.0017.

Texto completo da fonte

Resumo:

Tumefactive multiple sclerosis with the presence of tumefactive demyelinating lesions (TDL) is an infrequent manifestation of multiple sclerosis. It poses a diagnostic challenge, especially in attempts to differentiate it from a central nervous system neoplasm or other demyelinating disorders, such as neuromyelitis optica spectrum disorder (NMOSD). The article reports a case of a 40-year-old female during chronic steroid therapy administered due to an episode of idiopathic transverse myelitis. The patient developed tumour-like brain lesions in the left hemispheric parietal-occipital region. Th

Estilos ABNT, Harvard, Vancouver, APA, etc.

38

Aleksandrova, Iliyana, N. Topalov, E. Slavkova, et al. "Atypical imaging in children with multiple sclerosis – case presentation." Bulgarian Neurology 25, no. 1 (2024): 27–33. https://doi.org/10.5281/zenodo.15379692.

Texto completo da fonte

Resumo:

Atypical demyelinating lesions in multiple sclerosis (MS) (tumefactive demyelinating lesions, lesions with white matter cavitation, leukodystrophy-like lesions), although rare, pose serious differential diagnostic and therapeutic problems.We present 3 clinical cases of children, one with Balo concentric sclerosis and two with multiple sclerosis (MS), who had atypical magnetic resonance findings during the course of the disease or during the initial clinical manifestation. The first patient presented with an acute hemiparesis and hemihypesthesia with MRI evidence of a rounded tumor-like periven

Estilos ABNT, Harvard, Vancouver, APA, etc.

39

Czeisler, Barry M. "Emergent Management of Central Nervous System Demyelinating Disorders." CONTINUUM: Lifelong Learning in Neurology 30, no. 3 (2024): 781–817. http://dx.doi.org/10.1212/con.0000000000001436.

Texto completo da fonte

Resumo:

ABSTRACT OBJECTIVE This article reviews the various conditions that can present with acute and severe central nervous system demyelination, the broad differential diagnosis of these conditions, the most appropriate diagnostic workup, and the acute treatment regimens to be administered to help achieve the best possible patient outcomes. LATEST DEVELOPMENTS The discovery of anti–aquaporin 4 (AQP4) antibodies and anti–myelin oligodendrocyte glycoprotein (MOG) antibodies in the past two decades has revolutionized our understanding of acute demyelinating disorders, their evaluation, and their manag

Estilos ABNT, Harvard, Vancouver, APA, etc.

40

Bajagain, Madan, Tatsuki Oyoshi, Tomoko Hanada, et al. "Histopathological variation in the demyelinating sentinel lesion of primary central nervous system lymphoma." Surgical Neurology International 11 (October 15, 2020): 342. http://dx.doi.org/10.25259/sni_531_2020.

Texto completo da fonte

Resumo:

Background: Primary central nervous system lymphoma (PCNSL) is one of the least common malignant brain tumors. It is usually diagnosed initially as diffuse large B cell lymphoma (DLBCL). In rare cases, however, a demyelinating lesion referred to as a “sentinel lesion” precedes the actual diagnosis, which usually depicts two distinct patterns of inflammatory cells during histological analysis. This case report describes a unique histological finding and describes the recognized variations in sentinel lesion histopathology. Case Description: A 78-year-old female patient was found to have multipl

Estilos ABNT, Harvard, Vancouver, APA, etc.

41

Plowman, R. Skipper, and Hemant Varma. "Prognostic factors in Tumefactive demyelinating lesions: A retrospective study." Journal of the Neurological Sciences 428 (September 2021): 117591. http://dx.doi.org/10.1016/j.jns.2021.117591.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

42

Yapici, Zuhal, and Mefkure Eraksoy. "Bilateral Demyelinating Tumefactive Lesions in Three Children With Hemiparesis." Journal of Child Neurology 17, no. 9 (2002): 655–60. http://dx.doi.org/10.1177/088307380201700901.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

43

Al Malik, Yaser M. "Tumefactive demyelinating lesions: A literature review of recent findings." Neurosciences 29, no. 3 (2024): 153–60. http://dx.doi.org/10.17712/nsj.2024.3.20230111.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

44

Rozzanigo, Umberto, Pietro Bontempi, Sabrina Marangoni, Bruno Giometto, and Paolo Farace. "T2 Relaxometry in Tumefactive Demyelinating Lesions: A Case Study." Current Research in MRI 1, no. 3 (2023): 82–84. http://dx.doi.org/10.5152/currresmri.2022.222340.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

45

Silsby, Matthew, Pedro S. Lopez, Judy Spies, et al. "039 Estimating the health and economic burden of investigating tumefactive demyelination compared to conventional multiple sclerosis." Journal of Neurology, Neurosurgery & Psychiatry 90, e7 (2019): A13.3—A14. http://dx.doi.org/10.1136/jnnp-2019-anzan.36.

Texto completo da fonte

Resumo:

IntroductionTumefactive demyelinating lesions, defined as demyelinating lesions > 2cm in diameter, occur most commonly in association with multiple sclerosis (MS), and can pose a diagnostic challenge. The aim of this study was to estimate the cost and morbidity associated with the diagnostic investigation of patients with tumefactive demyelination (TD) compared to patients with conventional relapsing-remitting MS.MethodsRetrospective review of patients seen between 2013–2018 in clinics at the Brain and Mind Centre, Sydney; a centre with tertiary referral expertise in MS. Records were search

Estilos ABNT, Harvard, Vancouver, APA, etc.

46

Ikeda, Kristin M., Donald H. Lee, J. Alexander Fraser, Seyed Mirsattari, and Sarah A. Morrow. "Plasma Exchange in a Patient with Tumefactive, Corticosteroid-Resistant Multiple Sclerosis." International Journal of MS Care 17, no. 5 (2015): 231–35. http://dx.doi.org/10.7224/1537-2073.2014-078.

Texto completo da fonte

Resumo:

Tumefactive multiple sclerosis (MS) is an aggressive form of MS that can be difficult to treat with standard therapies. In severe MS relapses, plasma exchange (PLEX) has shown some benefit, but reports of its use in patients with tumefactive MS are limited. This article describes the successful use of PLEX in a patient with tumefactive MS. A 46-year-old right-handed woman with a recent diagnosis of MS presented with drowsiness, dysarthria, horizontal nystagmus, and quadriparesis. Her brain magnetic resonance images demonstrated multiple tumefactive demyelinating lesions in the medulla, bilater

Estilos ABNT, Harvard, Vancouver, APA, etc.

47

Menascu, S., S. Miron, A. Fatal, and A. Achiron. "PO-0846 Tumefactive Demyelinating Lesions In Juvenile-onset Multiple Sclerosis." Archives of Disease in Childhood 99, Suppl 2 (2014): A529.2—A529. http://dx.doi.org/10.1136/archdischild-2014-307384.1475.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

48

Menascu, S., and S. Miron. "OP68 – 2605: Tumefactive demyelinating lesions in juvenile-onset multiple sclerosis." European Journal of Paediatric Neurology 19 (May 2015): S22. http://dx.doi.org/10.1016/s1090-3798(15)30069-6.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

49

Minagar, A. "Dominant perivenular enhancement of tumefactive demyelinating lesions in multiple sclerosis." Yearbook of Neurology and Neurosurgery 2011 (January 2011): 105–6. http://dx.doi.org/10.1016/j.yneu.2010.12.048.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

50

Ikeguchi, Ryotaro, Yuko Shimizu, Kayoko Abe, et al. "Proton magnetic resonance spectroscopy differentiates tumefactive demyelinating lesions from gliomas." Multiple Sclerosis and Related Disorders 26 (November 2018): 77–84. http://dx.doi.org/10.1016/j.msard.2018.08.025.

Texto completo da fonte

Estilos ABNT, Harvard, Vancouver, APA, etc.

Oferecemos descontos em todos os planos premium para autores cujas obras estão incluídas em seleções literárias temáticas. Contate-nos para obter um código promocional único!